- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05196581
Efficacy of Breathox Device Inhalation Therapy in the Treatment of Acute Symptoms Associated With COVID-19 and in the Prevention of the Use of Health Resources (BREATH)
Randomized, Open-label Study to Evaluate the Efficacy of Breathox Device Inhalation Therapy in the Treatment of Acute Symptoms Associated With COVID-19 and in the Prevention of the Use of Health Resources in Patients With ≥ 18 Years Old
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Suzana Minamoto, Ph.D.
- Phone Number: +551438801663
- Email: suzana.tanni@unesp.br
Study Contact Backup
- Name: Luana Pagan, PhD
- Phone Number: +551438801663
- Email: luanapagan@alunos.fmb.unesp.br
Study Locations
-
-
São Paulo
-
Botucatu, São Paulo, Brazil, 18618687
- Hospital das Clínicas da Faculdade de Medicina de Botucatu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
A. Adult males or females (≥ 18 years of age), not hospitalized, diagnosed with SARS-CoV-2 infection by oropharyngeal RT-PCR or swab antigen test, with mild symptoms of infection.
B. Symptomatic subjects must have at least 1 of the following symptoms at inclusion: fever or fever perceived for more than 24 hours, headache, sore throat, nasal obstruction, dry cough, fatigue, chest pain, or choking sensation (no associated respiratory distress ), myalgia, anosmia, ageusia or gastrointestinal symptoms within 10 days of onset;
C. Subjects with arterial pulse oximetry (SpO2) saturation ≥ 92% in room air at inclusion;
D. Participants with the following hematological and biochemical laboratory parameters obtained within 7 days before D0:
- Hemoglobin > 9.0 g/dL-1
- Absolute Neutrophil Count ≥ 1000 mm-³
- Platelets ≥ 100,000 mm-3
- Creatinine clearance ≥ 30 mL/min-1 by Cockcroft-Gault formula
- Rapid negative pregnancy test for women of childbearing age. and. Participants must understand, sign and date the voluntary written consent form at the visit prior to any protocol-specific procedure;
E. Participants must be able and willing to comply with study visits and procedures as per protocol.
Exclusion Criteria:
A. Moderate or severe acute respiratory failure, or requiring non-invasive ventilation or oxygen, or with SpO2 <92% or tachypnea (respiratory rate ≥30 breaths/minute);
B. Serious and uncontrolled preexisting organ insufficiency, which prevents participation in the study by the investigator's judgment;
C. Diagnosis of previous asthma using inhaled or oral corticosteroids in the last four weeks;
D. Previous use, in the last ten days of randomization, of inhaled, oral or intravenous corticosteroids; hydroxychloroquine and dewormers.
E. Previous diagnosis of chronic obstructive pulmonary disease, even when not using any inhaled medication;
F. Pregnant or lactating women;
G. Use of any investigational or unrecorded product within the 3 month period or the 5 half-lives period prior to the baseline period, whichever is longer;
H. Any condition that, in the investigator's opinion, could compromise the participant's safety or adherence to the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: No intervation
Thirty-four subjects receive no intervention.
|
|
Active Comparator: Experimental intervation one
Thirty-three subjects receive dispersible NaCl powder, 8 mg per session per hour (one administration in each nostril and two oral inhalations), totaling 10 times a day, for ten days.
|
Dispersible NaCl powder 10 sessions
Other Names:
|
Active Comparator: Experimental intervation two
Thirty-three subjects will receive dispersible NaCl powder, 8 mg per session (one administration in each nostril and two oral inhalations) every 3 hours, totaling 5 times a day, for ten days.
|
Dispersible NaCl powder 5 sessions
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of days of symptom clinic improvement
Time Frame: 10 days after treatment
|
Number of days of symptom clinic improvement
|
10 days after treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BREA01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
Clinical Trials on Dispersible NaCl powder 10 sessions
-
University of OttawaRecruitingPain | EndometriosisCanada
-
University of California, San DiegoCompletedDepression | Anxiety Disorders and SymptomsUnited States
-
Institut de cancérologie Strasbourg EuropeNot yet recruiting
-
WestatEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedPNC Vaccine | HIV-infected Pregnant WomenBrazil
-
GlaxoSmithKlineCompleted
-
Johns Hopkins UniversityCenters for Medicare and Medicaid Services; Baltimore City Health DepartmentCompleted
-
Cyanotech CorporationUniversity of South FloridaCompleted
-
NYU Langone HealthSubstance Abuse and Mental Health Services Administration (SAMHSA)CompletedMood Disorders | Anxiety DisordersUnited States
-
Christopher BellCaliper FoodsActive, not recruiting
-
UConn HealthNational Institute on Drug Abuse (NIDA)Completed